Toward a Multidimensional Framework for Defining Remission in Atopic Dermatitis

<b><i><u></u></i></b> Defining remission in atopic dermatitis (AD) remains challenging due to heterogeneous criteria and inconsistent endpoints. Current approaches often conflate good disease control with true remission, and few integrate multidomain assessments. This review proposes a functional spectrum of treatment response, ranging from nonresponse to complete treatment-free remission, incorporating both duration and treatment context. The framework distinguishes complete control on therapy, durable control over extended periods, response maintained after dose tapering, and sustained improvement following treatment cessation. Clinical, patient-reported, and immunological dimensions are considered, with emphasis on practical applicability to trial design. Opportunities for innovation include wearable technology, patient-reported digital tools, and predictive analytics to capture real-time disease dynamics and identify candidates for deep remission. By adopting standardized definitions and composite endpoints informed by disease biology and patient experience, future trials can more accurately measure meaningful, durable outcomes. Standardized remission criteria will improve cross-study comparability, guide therapeutic development, and align clinical care with the goal of long-term, treatment-free disease control in AD.

Authors

Institutions

Publication Details

Journal
Dermatitis
Published
2026-02-06
DOI
https://doi.org/10.1177/17103568251406612
Primary Topic
Dermatology and Skin Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Toward a Multidimensional Framework for Defining Remission in Atopic Dermatitis

Jatin Patel, Peter Lio
Dermatitis
Dermatology and Skin Diseases
article

Toward a Multidimensional Framework for Defining Remission in Atopic Dermatitis

Jatin Patel, Peter Lio
article en

Abstract

<b><i><u></u></i></b> Defining remission in atopic dermatitis (AD) remains challenging due to heterogeneous criteria and inconsistent endpoints. Current approaches often conflate good disease control with true remission, and few integrate multidomain assessments. This review proposes a functional spectrum of treatment response, ranging from nonresponse to complete treatment-free remission, incorporating both duration and treatment context. The framework distinguishes complete control on therapy, durable control over extended periods, response maintained after dose tapering, and sustained improvement following treatment cessation. Clinical, patient-reported, and immunological dimensions are considered, with emphasis on practical applicability to trial design. Opportunities for innovation include wearable technology, patient-reported digital tools, and predictive analytics to capture real-time disease dynamics and identify candidates for deep remission. By adopting standardized definitions and composite endpoints informed by disease biology and patient experience, future trials can more accurately measure meaningful, durable outcomes. Standardized remission criteria will improve cross-study comparability, guide therapeutic development, and align clinical care with the goal of long-term, treatment-free disease control in AD.

Dermatitis
Northwestern University (US), University of Wisconsin–Madison (US), Wisconsin Division of Public Health (US)
Industry, innovation and infrastructure
Openalex Percentile: Top 65%
Dermatology and Skin Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.